The impact of aspirin combined with labetalol on coagulation function and pregnancy outcomes in pre-eclamptic pregnant women.

Abstract

Background: This study aimed to analyze the impact of aspirin combined with labetalol on coagulation function and pregnancy outcomes in women with pre-eclampsia.

Methods: A total of 98 pregnant women with pre-eclampsia admitted to our hospital from September 2019 to March 2021 were selected for the retrospective analysis. Patient records were reviewed and divided into a control group (n = 49) who received labetalol and an observation group (n = 49) who received aspirin combined with labetalol. Extracted from the case collection system and observed: clinical efficacy, occurrence of adverse pregnancy outcomes, and adverse reactions.

Results: The total effective rate in the observation group was higher than that in the control group. After treatment, the observation group had lower systolic blood pressure, diastolic blood pressure, D-D, Scr, β2-MG, and MA levels compared to the control group, and higher TT, PT and APTT levels. The occurrence rate of adverse pregnancy outcomes such as preterm delivery, intrauterine distress, postpartum hemorrhage, and fetal heart abnormalities was lower in the observation group than in the control group. There were no statistically significant differences in adverse reactions such as nausea, vomiting, hypotension, ocular tremor, and facial flushing between the two groups.

Conclusion: Aspirin combined with labetalol has ideal therapeutic efficacy in women with pre-eclampsia. It can enhance the antihypertensive effect, improve the coagulation status of the body, protect renal function, improve adverse pregnancy outcomes, and is considered safe and reliable, deserving adoption.